Ozempic vs Zepbound
A side-by-side look at Ozempic and Zepbound, two prescription medications advertised on TV. Informational only — not medical advice.
| US Ozempic | US Zepbound | |
|---|---|---|
| Generic name | semaglutide | tirzepatide |
| Drug class | GLP-1 Receptor Agonist | GIP/GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes | Chronic weight management, obstructive sleep apnea |
| Category | Diabetes | Weight Management |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Year approved | 2017 | 2023 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $420M | $300M |
| Common side effects | Nausea, Vomiting, Diarrhea, Abdominal pain | Nausea, Diarrhea, Vomiting, Constipation |
Frequently asked questions
Is Ozempic or Zepbound better?
Neither is universally "better." Ozempic (semaglutide) is used for type 2 diabetes, while Zepbound (tirzepatide) is used for chronic weight management, obstructive sleep apnea, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ozempic and Zepbound?
Ozempic is a GLP-1 Receptor Agonist made by Novo Nordisk, while Zepbound is a GIP/GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ozempic has the larger estimated TV advertising budget of the two.